Open AccessPlasmid-based CRISPR-Cas9 system efficacy for introducing targeted mutations in CD81 gene of MDA-MB-231 cell line
Author(s) -
Saeed Kaboli,
Hossein Rahimi,
Jose Thekkiniath,
Amir Hossein Taromchi,
Saeed Kaboli
Publication year - 2022
Publication title -
folia histochemica et cytobiologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.384
H-Index - 40
eISSN - 1897-5631
pISSN - 0239-8508
DOI - 10.5603/fhc.a2022.0007
Subject(s) - crispr , cas9 , biology , plasmid , genome editing , exon , cd81 , gene , subgenomic mrna , computational biology , genetics , microbiology and biotechnology , hepatitis c virus , virus
Breast cancer has been represented a challenging issue worldwide as it is one of the major leading causes of death among women. CD81 gene, a member of the tetraspanin protein family, has been associated with the development of human cancers. Genome editing technologies, particularly the CRISPR-Cas9 system, have shown rapid progress in gene function studies. In this study, we aimed to evaluate the ability of the CRISPR-Cas9 plasmid-based system to modify specific regions of the CD81 gene in the MDA-MB-231 breast cancer cell line.